Acacia Pharma Group plc Correction: Transparency Notification - Pdf Of Notification Attached
05 July 2021 - 11:02PM
UK Regulatory
TIDMACPH
THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION.
PUBLICATION RELATING TO A TRANSPARENCY NOTIFICATION
(ARTICLE 14, 1(ST) PARAGRAPH, OF THE LAW OF 2 MAY 2007 ON THE DISCLOSURE
OF MAJOR HOLDINGS)
-------------------------------------------------------------------------
Acacia Pharma Group plc
1. Summary of the notification
Cambridge, UK and Indianapolis, US -- 01 July 2021, 08:00 CEST:
Acacia Pharma Group plc has received a transparency notification
dated 30 June 2021 indicating that Coltrane Asset Management L.P.
now holds, by virtue of the sale of shares on 25 June 2021, 4.86%
of the voting rights of the company. Coltrane has therefore crossed
the threshold of 5%.
2. Content of notification
The notification dated 30 June 2021 contains the following
information:
-- Reason of the notification -- acquisition or disposal of voting
securities or tights
-- Notification by -- a parent undertaking or a controlling person
-- Persons subject to the notification requirement:
Name Address (for legal entities)
---------------------------------- -----------------------------------
Mandeep Manku 250 W 55(th) St 16C
New York, NY 10019
---------------------------------- -----------------------------------
Coltrane Asset Management Holdings 94 Solaris Avenue
Ltd Camana Bay, Grand Cayman KY1-1108,
Cayman Islands
---------------------------------- -----------------------------------
Coltrane Asset Management L.P. 94 Solaris Avenue
Camana Bay, Grand Cayman KY1-1108,
Cayman Islands
---------------------------------- -----------------------------------
-- Date on which the threshold is crossed -- 25 June 2021
-- Threshold that is crossed -- 5%
-- Denominator -- 93,713,951
-- Notified details:
Previous
A) Voting rights notification After the transaction
------------------ ------------ -----------------------------------------------------------
# of voting
rights # of voting rights % of voting rights
------------------ ------------ ------------------------------ ---------------------------
Holders of voting Linked Not linked Linked to Not linked
rights to securities to securities securities to securities
------------------ ------------ -------------- -------------- ----------- --------------
Mandeep Manku 0 0 0.00% 0.00%
------------------ ------------ -------------- -------------- ----------- --------------
Coltrane Asset
Management L.P. 4,931,684 4,844,404 0 4.86% 0.00%
------------------ ------------ -------------- -------------- ----------- --------------
Subtotal 4,844,404 4.86%
------------------ ------------ -------------- -------------- ----------- --------------
TOTAL 4,844,404 0 4.86% 0.00%
-------------- -------------- ----------- --------------
B) Equivalent
financial instruments After the transaction
----------------------- -----------------------------------------------------------------------------------
# of voting
rights
that may
be acquired
Exercise if the
Holders of equivalent Type of financial Expiration period instrument % of voting
financial instruments instrument date or date is exercised rights Settlement
----------------------- ------------------ ----------- ---------- ------------- ----------- ----------
TOTAL 0 0.00%
------------- -----------
# of voting % of voting
TOTAL (A+B) rights rights
------------------ ----------- ---------- ------------- -----------
CALCULATE 4,844,404 4.86%
----------------------------------------------------------------- ------------- -----------
Full chain of controlled undertakings through which the holding
is effectively held:
-- Coltrane Asset Management, L.P. is an investment advisor which manages
funds and accounts which hold the shares reported in this filing.
-- Coltrane Asset Management, L.P. can exercise the voting rights at its
discretion, without any instruction from its clients.
-- Coltrane Asset Management, L.P. is controlled by Coltrane Asset
Management Holdings, Ltd, which is controlled by Mandeep Manku.
3. Miscellaneous
-- This press release is available on Acacia Pharma Group plc's website
(https://acaciapharma.com/investors/regulatory-announcements)
-- The notification may be found on Acacia Pharma Group plc's website (
(https://acaciapharma.com/investors/regulatory-announcements)
Contacts
Acacia Pharma Group plc International Media
Mike Bolinder, CEO Mark Swallow, Frazer Hall, David
Gary Gemignani, CFO Dible
+44 1223 919760 / +1 317 505 1280 MEDiSTRAVA Consulting
IR@acaciapharma.com +44 20 7638 9571
acaciapharma@medistrava.com
US Investors Media in Belgium and the Netherlands
LifeSci Advisors Chris Van Raemdonck
Irina Koffler +32 499 58 55 31
+1 917-734-7387 chrisvanraemdonck@telenet.be
ikoffler@lifesciadvisors.com
Acacia Pharma Group plc
The Officers' Mess, Royston Road, Duxford, Cambridge, CB22 4QH,
United Kingdom
Company number 9759376
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on
the development and commercialization of new products aimed at
improving the care of patients undergoing significant treatments
such as surgery, other invasive procedures, or cancer chemotherapy.
The Company has identified important and commercially attractive
unmet needs in these areas that its product portfolio aims to
address.
Acacia Pharma's first product, BARHEMSYS(R) (amisulpride
injection) is marketed in the US for the management of
postoperative nausea & vomiting (PONV).
BYFAVO(TM) (remimazolam) for injection, a very rapid
onset/offset IV benzodiazepine sedative is approved and launched in
the US for use during invasive medical procedures in adults lasting
30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is
in-licensed from Paion UK Limited for the US market.
APD403 (intravenous and oral amisulpride), a selective dopamine
antagonist for chemotherapy induced nausea & vomiting (CINV)
has successfully completed one proof-of-concept and one Phase 2
dose-ranging study in patients receiving highly emetogenic
chemotherapy.
Acacia Pharma has its US headquarters in Indianapolis, IN and
its R&D operations are centered in Cambridge, UK. The Company
is listed on the Euronext Brussels exchange under the ISIN code
GB00BYWF9Y76 and ticker symbol ACPH.
www.acaciapharma.com
Attachment
-- TR-1BE_ACPH BB_06.30.21_ACPH_Signed (002)
https://ml-eu.globenewswire.com/Resource/Download/26cc08ff-1718-43ad-a681-8a6d8cc23d08
(END) Dow Jones Newswires
July 05, 2021 09:02 ET (13:02 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Apr 2023 to Apr 2024